All In Biotech

Drug Trial Radar · NCT05403450

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

33

Actual

Start

Feb 22, 2023

Primary completion

Dec 16, 2024

Study completion Jul 1, 2026

Sponsor

Lead sponsor
Taiho Oncology, Inc.Industry
Sponsor type
Industry
First posted
Jun 3, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2. As no safe and tolerable dosing for the combination of tolinapant and decitabine/cedazuridine was identified based on protocol defined criteria, Sponsor decided to halt recruitment and to not conduct Phase 2 of the study.

Conditions

  • Relapsed/Refractory Peripheral T-cell Lymphoma

Interventions

  • TolinapantDrug

    Capsule for oral administration

  • Decitabine + CedazuridineDrug

    Tablet for oral administration

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Dose Limiting Toxicities (DLTs)Time frame: Up to 54 months
  2. Phase 2: Antitumor Activity Assessed by Overall Response Rate (ORR) Based on 2014 Lugano Classification Using Computerized Tomography (CT) Imaging as the Primary ModalityTime frame: Up to 54 months

Locations

19 sites in 6 countries. Site status is shown where the registry gives one.

  • University of Colorado Anschutz Medical Campus Site #118

    Aurora, Colorado

  • Moffitt Cancer Center Site #157

    Tampa, Florida

  • Winship Cancer Institute of Emory University

    Atlanta, Georgia

  • NYU Langone Laura and Isaac Perlmutter Cancer Center Site #153

    New York, New York

  • University of Pennsylvania Site# 160

    Philadelphia, Pennsylvania

  • The University of Texas MD Anderson Cancer Center Site #101

    Houston, Texas

  • Concord Hospital

    Concord, New South Wales, Australia

  • Monash Medical Center

    Melbourne, Victoria, Australia

  • Institut Bergonié Site#553

    Bordeaux, France

  • Institut Paoli-Calmettes

    Marseille, France

  • U.O.C. di Ematologia Pad. 8IRCCS Azienda OspedalieroUniversitaria di Bologna Site#651

    Bologna, Italy

  • Fondazione IRCCS San Gerardo dei Tintori Site #655

    Monza, Italy

  • Ośrodek Badań Klinicznych Wczesnych Faz - Uniwersyteckie Centrum Kliniczne w Gdańsku

    Gdansk, Pomeranian Voivodeship, Poland

  • Hospital del Mar Site #704

    Barcelona, Spain

  • Hospital Universitario Fundación Jiménez Díaz Site #703

    Madrid, Spain

  • Hospital Universitario 12 de Octubre Site#710

    Madrid, Spain

  • Hospital Universitario Marqués de Valdecilla Site#711

    Santander, Spain

  • Hospital Universitario Virgen del Rocío

    Seville, Andalusia, Spain

  • Institut Català d'Oncologia - Hospital Duran i Reynals (ICO L'Hospitalet)

    Barcelona, Catalonia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.